{"disease":{"id":"chronic-myeloid-leukaemia","name":"chronic myeloid leukaemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05286528","title":"Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05893836","title":"Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia","phase":"","overall_status":"COMPLETED","enrollment_count":555,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01343173","title":"Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib","phase":"NA","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT01699217","title":"Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase","phase":"","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT05682924","title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","phase":"","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Samara State Medical University","has_results":false},{"nct_id":"NCT02546375","title":"A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands","phase":"","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02001818","title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Australasian Leukaemia and Lymphoma Group","has_results":false},{"nct_id":"NCT05376852","title":"Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05080829","title":"Myeloid Mutations Register in R/R CML","phase":"NA","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Grupo Cooperativo de Hemopatías Malignas","has_results":false},{"nct_id":"NCT02108951","title":"Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01475110","title":"Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib","phase":"","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}